Sunesis Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 7,956 3,754 5,000 33
Cost of Revenue - - - -
Gross Profit 7,956 3,754 5,000 33
Operating Expenses
Research and Development 28,891 29,185 22,563 14,433
Sales, General and Admin. 10,838 9,175 8,303 7,005
Non-Recurring Items - - - -
Other - - - -
Operating Income (31,773) (34,606) (25,866) (21,405)
Income From Continuing Operations
Add'l Income/Expense Items 92 (7,490) 5,984 (3,182)
Earnings Before Interest and Tax (31,681) (42,096) (19,882) (24,587)
Interest Expense 2,917 1,855 259 -
Earnings Before Tax (34,598) (43,951) (20,141) (24,587)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (34,598) (43,951) (20,141) (24,587)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (34,598) (43,951) (20,141) (24,587)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (34,598) (43,951) (20,141) (24,587)